ArticleP & T : a peer-reviewed journal for formulary management2019
Shingrix: A New Herpes Zoster Vaccine.
Article in P & T : a peer-reviewed journal for formulary management, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Review
- Engineering lipid nanoparticle-stabilized emulsions for spatiotemporal mRNA delivery and enhanced T cell immunity.Cell reports. Medicine · 2026Article
- Vaccination in Patients with Cardiovascular Disease: A Case-Based Approach and Contemporary Review.CJC open · 2025Review
- Uptake, Willingness, and Determinants of Herpes Zoster Vaccination in Adults with Chronic Diseases in Riyadh, Saudi Arabia.Healthcare (Basel, Switzerland) · 2025Article
- Risk of tuberculosis and hepatitis B reactivation during adalimumab use in the treatment of hidradenitis suppurativa.Scientific reports · 2025Article
- Clinical characteristics and treatment of varicella zoster virus central nervous system infection in an Australian tertiary hospital.Internal medicine journal · 2025Article
- An Exploratory Investigation of Representations of Herpes Zoster and Adjuvanted Recombinant Herpes Zoster Vaccination in a Sample of Fragile Adults in Italy.Pathogens (Basel, Switzerland) · 2025Article
- Vaccines in Dermatology-Present and Future: A Review.Vaccines · 2025Review
- Article
- Lipo-pam™ adjuvanted herpes zoster vaccine induces potent gE-specific cellular and humoral immune responses.NPJ vaccines · 2024Article
- Two cases of atypical herpes zoster in people taking oral Janus kinase inhibitors.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2024Article
- Anti-Herpes Zoster Vaccination of Fragile Patients in Hospital Setting: A Nudge Intervention in Italy.Vaccines · 2024Article
- The relationship between Zoster serology, vaccination uptake and infection rates: a single-centre cross-sectional study.Rheumatology advances in practice · 2024Article
- Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Review
- Protective RNA nanovaccines againstFrontiers in immunology · 2023Article
- Poly(hydrophobic Amino Acids) and Liposomes for Delivery of Vaccine against Group A Streptococcus.Vaccines · 2022Article
- Review
- The frequency of interleukin-1β-producing monocytes is significantly associated with varicella-zoster responses of nursing home residents.Clinical and experimental immunology · 2021Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shingrix, a new vaccine for herpes zoster.
Identifiers
31258310PMC6590925W2981218950What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.